Ionis Pharmaceuticals (IONS) EBITDA Margin (2009 - 2026)
Ionis Pharmaceuticals' quarterly EBITDA Margin came in at 47.72% in Q1 2026, up 6387.0% year-on-year from 0.74% in Q1 2025, and up 54.76% quarter-over-quarter from 105.47% in Q4 2025.
Ionis Pharmaceuticals has reported EBITDA Margin for 18 years, with the latest figure at 47.72% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 6387.0% year-over-year to 47.72%; the trailing twelve-month figure through Mar 2026 stood at 57.92% (up 794.0% YoY), and the FY2025 full-year result was 8.45%, up 525.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 47.72%, up from 105.47% in the prior quarter.
- The five-year high for EBITDA Margin was 6990.8% in Q2 2025, with the low at 136.95% in Q4 2022.
- Average EBITDA Margin over 5 years is 340.85%, with a median of 63.92% recorded in 2022.
- Year-over-year, EBITDA Margin plunged 18709 bps in 2022 and surged 702014 bps in 2025.
- Tracing IONS's EBITDA Margin over 5 years: stood at 136.95% in 2022, then jumped by 99 bps to 1.89% in 2023, then plunged by 2493 bps to 48.91% in 2024, then sank by 116 bps to 105.47% in 2025, then surged by 55 bps to 47.72% in 2026.
- The last three EBITDA Margin figures came in at 47.72% (Q1 2026), 105.47% (Q4 2025), and 102.21% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Ionis Pharmaceuticals | 12.61 Bn | 10.69 Bn | 243.11 Mn | -47.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.72% |
| Dec 31, 2025 | -105.47% |
| Sep 30, 2025 | -102.21% |
| Jun 30, 2025 | 6,990.80% |
| Mar 31, 2025 | -111.59% |
| Dec 31, 2024 | -48.91% |
| Sep 30, 2024 | -111.09% |
| Jun 30, 2024 | -29.34% |
| Mar 31, 2024 | -125.12% |
| Dec 31, 2023 | -1.89% |
| Sep 30, 2023 | -99.35% |
| Jun 30, 2023 | -47.87% |
| Mar 31, 2023 | -87.45% |
| Dec 31, 2022 | -136.95% |
| Sep 30, 2022 | -37.03% |
| Jun 30, 2022 | -63.92% |
| Mar 31, 2022 | -40.52% |
| Dec 31, 2021 | 50.14% |
| Sep 30, 2021 | -64.50% |
| Jun 30, 2021 | -58.03% |
| Mar 31, 2021 | -82.41% |
| Dec 31, 2020 | -55.01% |
| Sep 30, 2020 | -22.82% |
| Jun 30, 2020 | -398.11% |
| Mar 31, 2020 | -45.83% |
| Dec 31, 2019 | 579.23% |
| Sep 30, 2019 | 10.09% |
| Jun 30, 2019 | -313.78% |
| Mar 31, 2019 | 81.02% |
| Dec 31, 2018 | 30.81% |
| Sep 30, 2018 | -185.72% |
| Jun 30, 2018 | -42.70% |
| Mar 31, 2018 | -11.00% |
| Dec 31, 2017 | -13.78% |
| Sep 30, 2017 | 9.56% |
| Jun 30, 2017 | 5.74% |
| Mar 31, 2017 | 16.83% |
| Dec 31, 2016 | 316.58% |
| Sep 30, 2016 | 14.52% |
| Jun 30, 2016 | -127.18% |
| Mar 31, 2016 | -148.21% |
| Dec 31, 2015 | -122.05% |
| Sep 30, 2015 | -98.00% |
| Jun 30, 2015 | 48.95% |
| Mar 31, 2015 | -14.91% |
| Dec 31, 2014 | 11.88% |
| Sep 30, 2014 | -48.78% |
| Jun 30, 2014 | -11.65% |
| Mar 31, 2014 | -105.35% |
| Dec 31, 2013 | -47.00% |
| Sep 30, 2013 | -108.14% |
| Jun 30, 2013 | -68.94% |
| Mar 31, 2013 | 3.75% |
| Dec 31, 2012 | -280.85% |
| Sep 30, 2012 | -325.50% |
| Jun 30, 2012 | 7.81% |
| Mar 31, 2012 | -79.43% |
| Dec 31, 2011 | -57.45% |
| Sep 30, 2011 | -137.28% |
| Jun 30, 2011 | -56.64% |
| Mar 31, 2011 | -76.17% |
| Dec 31, 2010 | -60.02% |
| Sep 30, 2010 | -31.26% |
| Jun 30, 2010 | -79.45% |
| Mar 31, 2010 | -16.31% |
| Dec 31, 2009 | 14.71% |
| Sep 30, 2009 | -38.83% |
| Jun 30, 2009 | -15.57% |